🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I read an insanely beautiful ML paper yesterday. It made me happy—and also sad. There is an infinite list of incredible things to learn about. The orchard of science is far too expansive for one person to traverse in any detail. And that principle extends to everything. There

Axiom Bio is transforming toxicity prediction with AI. Drug toxicity is an extraordinary problem. Even the best drug making organizations in the world can be knee-capped by unforeseen adverse events in the clinic. Consider Pfizer's recent discontinuation of danuglipron as just

Random thought: the O.G. architecture advance in ML came from bio (perceptrons) Now, most of BioML is the careful application of existing techniques (transformers, diffusion, flow matching, etc.) to biological data. Should we ever expect computational biologists to introduce

The Arc Institute keeps crushing it. Big step up in specificity and insertion efficiency for human genome engineering with bridge RNAs.

Object-oriented programming (OOP) was originally inspired by biology. There's a lot of excitement about applying CS and AI to biology, but I always love to collect examples of times when inspiration flowed the opposite direction. In doing research for an upcoming essay, I

Only two biotech investors (Nisa Leung and Bob Nelsen) made this year's Midas List. When the phoenix rises from the ashes and all of the pent up scientific progress causes us to break out of the current doom loop, my bet is that the number will be much higher over time.

Exclusive: Amplify Partners has raised $200 million for its first biotech-specific fund Targeting ~20 investments of $1.5m-$10m in pre-seed/seed/Series A-stage startups. The Silicon Valley VC has also hired Elliot Hershberg as a partner: endpoints.news/amplify-raises…

🧵1/ We Tahoe Therapeutics (Formerly Vevo) just published a new post on the Tahoe blog—a story of how we used Tahoe-100M, the world’s largest drug-perturbed single-cell dataset, to find compounds that upregulate MHC-I and make tumors more visible to the immune system. Here’s how 🧬🔍👇

New funds, new look, same Amplify. Announcing our $900M 6th set of funds, our first ever digital bio fund, and our new logo and site. The first (and best) investor for technical founders. amplifypartners.com/blog-posts/fun…

Awesome take by Carl June at the FDA's cell & gene therapy roundtable. Before considering trade regulations, we should look in the mirror and see what we can improve! There probably is a place for IITs in the US system.

To replace animal testing with AI, we need MASSIVE human datasets. Today, we're thrilled to share Axiom's new data exploration tool, providing the ability to visually explore the world's largest primary human liver toxicity dataset. Built with Axiom's proprietary wetlab

I was in Boston this week for BIO. As a SF Biohub maximalist, I’ve got to admit: the summer vibes in Cambridge are immaculate. It’s hot and humid, but the street canopy provides some shade. People escape their stuffy brownstones to lounge in the park. Conversations about